
The FDA has approved Roche's Wilserdly with everolimus for previously treated, ESR1-mutated advanced breast cancer that is HR-positive and HER2-negative. 🔗 Full story: buff.ly/BKNxh0b #BreastCancer #WomensHealth #FDAApproval #CancerTreatment #Oncology
















